View Older Stories
-
Berkowitz's Fairholme Picks Up Pharma Stakes, and Cisco (CSCO); Swaps General Growth (GGP) for Brookfield (BAM)
-
George Soros' Hedge Fund Slashes Stake In Gold ETF (GLD), Raises Stake in Citi (C) and AT&T (T)
-
Notable Analyst Rating Changes 03/31: (TSLA) (ARMH) (EMR) Upgraded; (OPEN) (CBE) (BMY) Downgraded
-
Notable 52-Week Highs and Lows of the Day 03/25: (ORCL) (BMY) (ACN) High; (BBY) (MNOV) Low
-
Daily State of the Markets 02/07: Irrelevant?
-
Paulson's Paulson & Co. Keeps Gold Rush Alive, Moves Out of Goldman and Increases Citi Stake (C, GS, ABX, APC, XOM, More...)
-
Citi on U.S. Major Pharmaceuticals: 2Q10 Outperformance Expected
-
Citi Maintains Estimates and 'Buy' Ratings on Merck (MRK) and Bristol-Myers (BMY); ADA Data Supports Our Januvia/Onglyza Long-Term Outlook
-
Notable Analyst Rating Changes 06/11: SQNM, SVVS, BMY, X Upgraded; LGF, AGU, WAG, THO Downgraded
-
Citi Upgrades Bristol-Myers Squibb (BMY) to Buy; Solid Pipeline Progress
-
Citi & Leerink Swann Upgrade Bristol-Myers (BMY) to Buy/Outperform
-
Notable Analyst Rating Changes 06/07: BMY, EGLE, CELG, NILE Upgraded; BP, TEL, SPWRA, ABT Downgraded
-
Citi 2010 Healthcare Conference Key Takeaways - MRK, PFE, BMY, ISIS, NPSP, & MYGN
-
Citi Comments on Disease-Modifying Antirheumatic Drug Market - 'Not Immune to a Tough Economy'
-
Active equity option families in first 30-minutes of trading according to Track Data are: C AAPL BAC BMY
-
Citi Issues Q1 Preview on U.S. Major Pharmaceuticals; Merck (MRK) Remains 'Top Pick'
-
Notable Analyst Rating Changes: MS, BA, UNH, INTC, UPL, FTO, More Upgraded; BMY, CHK, BSX, MELI, More Downgraded
-
Citi Downgrades Bristol-Myers (BMY) to Hold
-
Citi Sees 80% Upside For Mead Johnson (MJN) In Potential Buyout
-
Bristol-Myers Squibb (BMY) and Mead Johnson (MJN) Announce Results of Stock Exchange Offer
-
Bristol-Myers Squibb (BMY) and Mead Johnson (MJN) Announce Preliminary Results of Stock Swap
-
Active equity option families in first 30 minutes of trading according to Track Data are: C BMY BAC RIMM
-
Bristol-Myers Squibb (BMY) and Mead Johnson (MJN) Announce Common Exchange Offer
-
Active equity option families in first 60 minutes of trading: C BMY AAPL BAC
-
Notable Analyst Rating Changes 8/28: JCG, WSM, NOK, ARUN Upgraded; POT, MOS, BA, ENER, BMY Downgraded
-
David Moenning�s Daily State of the Markets: 8/28
-
Morning Movers 7/23: MEDX, ISRG, SANM, AFFX, MNI, CCMP, SPF Higher; FREE, CRA, CTIC, MCO, CIT, PSUN, TEX Lower
-
Notable Analyst Rating Changes 7/15: GS, ALU, ICE, MCO, ADBE, MI Upgraded; PTR, PAR, UFS, PCL Downgraded
-
Sanofi-Aventis (SNY) On the Prowl For A Mega-Deal In the U.S.?
-
Elan (ELN) Up On Renewed Takeover Talk
-
Elan (ELN) Jumps On Possible Bristol-Myers Stake
-
David Moenning's Daily State of the Markets: 4/29
-
Notable Analyst Rating Changes 4/29: ATVI, OZM, AMX, DNDN Upgraded; BMY, WFMI, M, SFD Downgraded
-
David Moenning's Daily State of the Markets: 4/28
-
Notable Analyst Rating Changes 4/3: RIMM, DVN, ICE, ELN Upgraded; DIS, BMY, MON, AKAM Downgraded
-
Mead Johnson (MJN) IPO Looks On Track
-
David Moenning's Daily State of the Markets: 1/27
-
Unusual 11 Mid-Day Movers 1/14: FAZ, EROC, ZGEN, CAMP Higher; STSA, FNB, C, BPZ Lower
-
Morning Movers 1/13: ZymoGenetics (ZGEN) Up On Bristol-Myers Deal; Lexmark (LXK) Down On Guidance
-
Unusual 11 Mid-Day Movers 12/12: GGP, PLD, EXEL, MAC Higher; LAD, HWD, AXL, PKI Lower
-
David Moenning's Daily State of the Markets: 12/10
-
Notable Analyst Rating Changes 12/10: RTP, BMY, HE Upgraded; GE, NUE, EBAY, ERTS Downgraded
-
Citi Upgrades Bristol-Myers Squibb (BMY) to Buy
-
Citi Issues List of 50 Highest Dividend Yield Stocks (MIC, FLY, AYR, GCI, OMX, STI, More...)
-
David Moenning's Daily State of the Markets: 10/23
-
Notable Analyst Rating Changes 10/08: BMY, NUE, SYMC Upgraded; TM, X, UPS, F, GM Downgraded
-
David Moenning's Daily State of the Markets: 10/08
-
Notable Mergers and Acquisitions of the Day 9/29: C/WB, IMCL, VSH/IRF
-
StreetInsider.com Morning Movers 9/29: Wachovia (WB) Trashed On FDIC Assisted Fire-Sale To Citi (C); Financial Slammed
-
Mead Johnson Nutrition (MJN) Files $1B IPO
